Key Highlights

  • 0.66 is the negative consensus EPS estimate per the screener snapshot for PAVmed Inc. (NASDAQ:PAVM), which is due to report third quarter 2026 results before the market opens on November 13, 2026.
  • 0.87 is the second quarter 2026 GAAP loss per share, on Revenue of USD 33 thousand versus USD 6 thousand a year earlier, while six-month revenue was USD 55 thousand and the six-month loss was 3.17 per share.
  • 3.8 million is the USD cash balance at June 30, 2026, up from USD 1.5 million at December 31, 2025, against operating expenses of about USD 7.1 million in the second quarter.
  • 12.83 million is the USD market Capitalization per the screener snapshot, a nano-cap level, while the company holds about 15% of Lucid Diagnostics, whose EsoGuard test processed 2,770 tests in the second quarter.

What Investors Expect From PAVmed Inc. (NASDAQ:PAVM) on November 13, 2026

PAVmed is listed to report third quarter 2026 results before the market opens (BMO) on November 13, 2026, and a third quarter Business update call is also listed for that date. The exact call time was not found in published coverage. The consensus estimate per the screener snapshot is a loss of USD 0.66 per share, better than the second quarter GAAP loss of USD 0.87 per share. Market capitalization per the screener snapshot is USD 12.83 million, which carries nano-cap risk.

The Rationale: Last Reported Quarter and Management Outlook for PAVmed Inc. (NASDAQ:PAVM)

For the quarter ended June 30, 2026, revenue was USD 33 thousand, operating expenses were about USD 7.1 million including USD 0.9 million of stock-based compensation, and the non-GAAP adjusted net loss was about USD 1.7 million, or USD 0.27 per share. No numerical guidance was found. Management points to a PortIO FDA meeting request planned for the fourth quarter of 2026 and a Veris Health implantable monitor submission targeted for early 2027, although the first quarter call referred to year-end 2026. Lucid Diagnostics posted USD 1.5 million of second quarter revenue and secured a first laboratory benefit manager coverage policy.

Valuation, Liquidity and Risks for PAVmed Inc. (NASDAQ:PAVM)

Per the screener snapshot, Market Value is USD 12.83 million. Cash was USD 3.8 million at June 30, 2026, and a USD 15 million senior secured note matures in February 2029, with interest-only quarterly payments, according to the first quarter call. About 7.3 million shares were cited in that period, so the snapshot value implies roughly USD 1.76 per share, calculated. Further commercial expansion depends on raising capital, which could dilute holders. Nano-cap stocks can be Illiquid and volatile, and results depend on regulatory clearances and coverage decisions outside management control.

Where Things Stand

Where things stand: PAVmed Inc. (NASDAQ:PAVM) reports third quarter 2026 results before the market opens on November 13, 2026, with a consensus EPS estimate of -0.66 and a market value of USD 12.83 million per the screener snapshot. The second quarter brought revenue of USD 33 thousand, a GAAP loss of USD 0.87 per share and cash of USD 3.8 million. The multi-subsidiary model spans Lucid Diagnostics, Veris Health, PortIO and Octeris, so investors will watch cash burn, EsoGuard test volumes and FDA timelines. Figures in the reconciliation tables did not tie cleanly in published coverage. This article is informational and is not Investment advice.